



CSE: VP
OTC: VDQSF
FSE: 1JV1

NEWS RELEASE

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

Vodis Files Response with Health Canada

August 12, 2019, Vancouver, British Columbia - Vodis Pharmaceuticals Inc. (CSE: VP, FSE: 1JV1) (“Vodis” or the “Company”) reports that it has filed a comprehensive response to Health Canada’s request for information and clarification. Given Health Canada’s recent requirement for new applicants to have a fully built facility, the Company anticipates a quick assessment of its response package. Health Canada has also reassured the Company that its long-standing application remains at the front of Health Canada’s processing queue.

For further information please contact:

Mark Lotz, Chief Executive Officer

Email: mark@vodis.ca

or

Dr. Earl Oliver

Email: earl@vodis.ca

Twitter: @eaoliver

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

This news release contains “forward-looking information” within the meaning of applicable securities laws including statements relating to the outlook of the business of the Company, the Company’s intention to complete the private placement financing, the potential granting of a cultivation licence by Health Canada, and planned expenditures for upgrades and other renovations at the Company’s Delta, BC, and Washington facilities. Although the Company believes considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements, depending on, among other things, the risks that the private placement financing may not close for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placement financing may differ from those that currently are contemplated. The statements in this news release are made as of the date of this release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.